Tharimmune's Bold Steps in Addressing Opioid Challenges
Tharimmune, Inc., a clinical-stage biotechnology company, is making waves with its lead asset, TH104, aimed at tackling the severe challenges posed by ultrapotent opioids, including fentanyl. As a company focused on innovative therapies for inflammation and critical medical needs, Tharimmune is committed to expanding its therapeutic offerings.
Participation in Upcoming Fall Conferences
The company is gearing up for important upcoming conferences that present an excellent opportunity to showcase its innovative solutions. Tharimmune will participate in three major events, allowing the team to share new findings and connect with other professionals in the field. The venues for these conferences are renowned for gathering key stakeholders in the healthcare and pharmaceutical industries.
American College of Gastroenterology (ACG) Annual Scientific Meeting
One standout event will be the ACG Annual Scientific Meeting, scheduled to take place in late October. This meeting is a platform for sharing critical research and insights into gastrointestinal health, where the Tharimmune team will present findings related to TH104 and its pivotal role in addressing opioid-related complications.
The Liver Meeting® 2025
Following the ACG meeting, Tharimmune will also be featured at The Liver Meeting, which focuses on liver diseases and their treatment. This significant gathering will occur in early November, presenting a valuable chance to discuss the implications of TH104 on patients with liver conditions affected by opioid use.
AAPS PharmSci 360 Annual Meeting
Shortly after The Liver Meeting, the AAPS PharmSci 360 will host discussions surrounding pharmaceutical sciences across various platforms. Tharimmune’s presence at this event further emphasizes its dedication to advancing the scientific community’s understanding of opioid-related therapies.
The Vision Behind TH104
TH104 is designed to mitigate respiratory and nervous system depression among military personnel and emergency responders exposed to high-potency opioids. With its comprehensive pipeline, Tharimmune aims not only to target opioid effects but also to address chronic itching associated with primary biliary cholangitis and autoimmune diseases through innovative solutions like TH023.
About Tharimmune, Inc.
Tharimmune is a dynamic player in the biotechnology sector, focused on immunology, inflammation, and oncology. The company is committed to developing a robust portfolio of therapeutic candidates with a clear focus on patient-centered care. Their proprietary EpiClick Technology is set to revolutionize treatment approaches against solid tumors, showcasing Tharimmune's drive for innovation.
For those interested in the specifics of Tharimmune's progress, further details can be found at their official website.
Frequently Asked Questions
What is TH104 primarily aimed at treating?
TH104 is primarily developed to combat respiratory and nervous system depression caused by high-potency opioids.
Which conferences will Tharimmune be attending in the coming months?
Tharimmune will be participating in the ACG Annual Scientific Meeting, The Liver Meeting® 2025, and AAPS PharmSci 360.
What other indications is Tharimmune targeting?
The company is also focusing on chronic pruritus related to primary biliary cholangitis and other autoimmune diseases.
How does Tharimmune support patient-centered innovation?
Tharimmune emphasizes innovative therapeutic approaches designed specifically for clinical needs, showcasing dedication to improving patient outcomes.
What technology is Tharimmune utilizing to enhance its therapeutic candidates?
Tharimmune employs EpiClick Technology to target multiple solid tumors effectively, along with a partnership with OmniAb for antibody discovery.
